Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRTX NASDAQ:IMA NASDAQ:SGMT NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.21-2.4%$0.97$0.74▼$2.30$233.91M1.72.30 million shs1.79 million shsIMAImageneBio$5.29-10.5%$5.71$3.94▼$18.00$62.97M0.731.02 million shs75,284 shsSGMTSagimet Biosciences$7.71+0.9%$5.83$3.08▼$11.41$248.95M3.63.39 million shs962,338 shsVYGRVoyager Therapeutics$4.05+2.3%$4.04$2.64▼$5.55$239.25M1.26489,386 shs639,686 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics0.00%+3.33%+49.04%-1.59%-45.01%IMAImageneBio0.00%-1.83%+29.32%-14.47%-54.82%SGMTSagimet Biosciences0.00%-4.86%+36.67%+37.66%+128.74%VYGRVoyager Therapeutics0.00%+6.17%+1.02%+7.61%+20.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.21-2.4%$0.97$0.74▼$2.30$233.91M1.72.30 million shs1.79 million shsIMAImageneBio$5.29-10.5%$5.71$3.94▼$18.00$62.97M0.731.02 million shs75,284 shsSGMTSagimet Biosciences$7.71+0.9%$5.83$3.08▼$11.41$248.95M3.63.39 million shs962,338 shsVYGRVoyager Therapeutics$4.05+2.3%$4.04$2.64▼$5.55$239.25M1.26489,386 shs639,686 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics0.00%+3.33%+49.04%-1.59%-45.01%IMAImageneBio0.00%-1.83%+29.32%-14.47%-54.82%SGMTSagimet Biosciences0.00%-4.86%+36.67%+37.66%+128.74%VYGRVoyager Therapeutics0.00%+6.17%+1.02%+7.61%+20.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRTXHeron Therapeutics 2.20Hold$4.50271.90% UpsideIMAImageneBio 2.00Hold$26.50400.95% UpsideSGMTSagimet Biosciences 2.67Moderate Buy$28.63271.27% UpsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50307.41% UpsideCurrent Analyst Ratings BreakdownLatest IMA, VYGR, SGMT, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/26/2026SGMTSagimet Biosciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.003/25/2026VYGRVoyager Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/17/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRTXHeron Therapeutics$154.90M1.47N/AN/A$0.07 per share17.29IMAImageneBio$800K70.42N/AN/A$11.91 per share0.44SGMTSagimet Biosciences$2M125.60N/AN/A$3.42 per share2.25VYGRVoyager Therapeutics$40.37M6.06N/AN/A$3.53 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRTXHeron Therapeutics-$20.19M-$0.13N/A10.08N/A-13.04%N/A-4.62%5/11/2026 (Estimated)IMAImageneBio-$45.35M-$8.07N/AN/AN/AN/A-36.53%-32.28%N/ASGMTSagimet Biosciences-$51.04M-$1.57N/AN/AN/AN/A-40.85%-38.63%5/14/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$2.03N/AN/AN/A-319.61%-53.03%-40.56%5/11/2026 (Estimated)Latest IMA, VYGR, SGMT, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SGMTSagimet Biosciences-$0.39N/AN/AN/AN/AN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03N/AN/AN/A$36.72 millionN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/A3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/A3/9/2026Q4 2025VYGRVoyager Therapeutics-$0.54-$0.46+$0.08-$0.46$10.49 million$13.46 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRTXHeron Therapeutics10.592.481.51IMAImageneBioN/A12.4912.49SGMTSagimet BiosciencesN/A22.8222.82VYGRVoyager TherapeuticsN/A7.647.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRTXHeron Therapeutics80.01%IMAImageneBio75.00%SGMTSagimet Biosciences87.86%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipHRTXHeron Therapeutics5.86%IMAImageneBio5.94%SGMTSagimet Biosciences14.70%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableIMAImageneBio7010.65 million10.02 millionNot OptionableSGMTSagimet Biosciences832.58 million27.80 millionOptionableVYGRVoyager Therapeutics10060.42 million56.56 millionOptionableIMA, VYGR, SGMT, and HRTX HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street ZenMay 9 at 1:34 AM | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings ResultsMay 7 at 10:16 PM | marketbeat.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7 at 7:01 PM | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7 at 4:01 PM | globenewswire.comVoyager Therapeutics (VYGR) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Above Fifty Day Moving Average - Here's WhyApril 22, 2026 | marketbeat.comVoyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026April 13, 2026 | seekingalpha.comAlfred Sandrock Sells 11,511 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockApril 4, 2026 | insidertrades.comVoyager Therapeutics (VYGR) price target increased by 12.22% to 17.17March 27, 2026 | msn.comVoyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum TranscriptMarch 23, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)March 19, 2026 | theglobeandmail.comGuggenheim Remains a Buy on Voyager Therapeutics (VYGR)March 13, 2026 | theglobeandmail.comDoes Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?March 12, 2026 | finance.yahoo.comVoyager Therapeutics: Q4 Earnings SnapshotMarch 10, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesMarch 9, 2026 | zacks.comVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 9, 2026 | globenewswire.comVoyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptMarch 3, 2026 | seekingalpha.comTodd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockFebruary 27, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThese 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Corning Beats Q1 Estimates but Drops 9% on Guidance MissBy Ryan Hasson | April 29, 2026Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales TankBy Leo Miller | April 27, 2026Alcoa Rebounds as Aluminum Tightens, But a Q1 Miss Tests the RallyBy Jessica Mitacek | April 22, 2026IMA, VYGR, SGMT, and HRTX Company DescriptionsHeron Therapeutics NASDAQ:HRTX$1.21 -0.03 (-2.42%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.23 +0.02 (+1.24%) As of 05/8/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.ImageneBio NASDAQ:IMA$5.29 -0.62 (-10.49%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.54 +0.25 (+4.73%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Sagimet Biosciences NASDAQ:SGMT$7.71 +0.07 (+0.92%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.66 -0.05 (-0.70%) As of 05/8/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Voyager Therapeutics NASDAQ:VYGR$4.05 +0.09 (+2.27%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.02 -0.03 (-0.74%) As of 05/8/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
